tegavivint
Small moleculeexperimental
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 15, 2018 (NCT03459469)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Colorectal Neoplasms · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Hepatoblastoma · Phase 1/Phase 2
- Leukemia · Phase 1
- Lung Neoplasms · Phase 1
- Lymphoma · Phase 1
- Lymphoma, B-Cell · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Neuroblastoma · Phase 1/Phase 2
- Osteosarcoma · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
- Sarcoma, Ewing · Phase 1/Phase 2
- Wilms Tumor · Phase 1/Phase 2
Mechanism of action
- Catenin beta-1ANTAGONIST
CTNNB1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H]1C[C@H](C)CN(S(=O)(=O)c2ccc3c(c2)C(=NO)c2cc(S(=O)(=O)N4C[C@H](C)C[C@H](C)C4)ccc2C3=NO)C1- Mol. weight
- 588.75 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3601411 ↗
Also known as
- tegavivint
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07144254 | Phase 1 | Oct 31, 2025 | Emory University, Iterion Therapeutics |
| NCT05797805 | Phase 1/Phase 2 (Phase 2) | Sep 13, 2023 | Iterion Therapeutics |
| NCT05755087 | Phase 1 | Mar 6, 2023 | Ohio State University |
| NCT04851119 | Phase 1/Phase 2 (Phase 2) | Oct 29, 2021 | National Cancer Institute (NCI) |
| NCT04874480 | Phase 1 | Sep 27, 2021 | University of Texas at Houston |
| NCT04780568 | Phase 1 | Apr 1, 2021 | Ohio State University |
| NCT03459469 | Phase 1 | Jul 15, 2018 | Iterion Therapeutics |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Iterion Therapeutics | For profit | 3 | 2 | 2 | 2018 |
| Ohio State University | Academic/Hospital | 2 | 2 | 1 | 2021 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2021 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2021 |
5 organizations
Page 1 / 1